Streptococcus Pneumoniae Serotype 20A Conjugate Vaccine
This is a pneumococcal conjugate vaccine targeting Streptococcus pneumoniae serotype 20a, a bacterial pathogen that can cause serious infections including pneumonia, meningitis, and bloodstream infections. The vaccine works by linking the capsular polysaccharide antigen of serotype 20a to the diphtheria CRM197 protein carrier, which helps stimulate a stronger and longer-lasting immune response, particularly in young children whose immune systems may not respond well to polysaccharide antigens alone.
A conjugate vaccine designed to prevent pneumococcal disease caused by Streptococcus pneumoniae serotype 20a through enhanced immune response via diphtheria protein carrier technology.
Key facts at a glance
- RxNorm
- 2686920
- Generic
- Streptococcus Pneumoniae Serotype 20a Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Capvaxive
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive pneumococcal disease, pneumonia, and other serious infections caused by Streptococcus pneumoniae serotype 20a. This serotype is among those included in newer pneumococcal conjugate vaccine formulations designed to expand coverage against additional circulating strains.
The vaccine contains the capsular polysaccharide antigen from S. pneumoniae serotype 20a, which is chemically conjugated to the non-toxic CRM197 mutant diphtheria toxin protein. This conjugate structure converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, enabling stronger antibody responses, immunological memory, and effectiveness in infants and young children.
Like other pneumococcal vaccines, this vaccine is part of broader immunization strategies targeting multiple serotypes. Administration should follow established immunization schedules and guidelines. Individuals with known hypersensitivity to any vaccine component should not receive the vaccine. Consultation with healthcare providers is essential for determining appropriate vaccination based on age, risk factors, and prior vaccination history.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 31, 2026. · Read our editorial policy